Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07679919 · ClinicalTrials.gov registry record · Phase 1
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
A Phase 1 study, sponsored by Luminary Therapeutics.
- Not yet
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT07679919: Clinical Trial Phase 1 study, sponsored by Luminary Therapeutics.
NCT07679919 is a Phase 1 study that has not yet begun recruiting, run by Luminary Therapeutics. The registered enrollment target is 27 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07679919, a Phase 1 study, has not yet begun recruiting, sponsored by Luminary Therapeutics.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory hematologic malignancies, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory hematologic malignancies, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against refractory hematologic malignancies using a single lymphodepletion regimen and using a BAFF CAR-T cell manufacturing process.
Primary Outcome
Incidence and severity of treatment-emergent adverse events
Interventions
- BIOLOGICAL LMY-922
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2026-09 |
| Est. Completion | 2029-04 |
| Phase | Phase 1 |
What is known before NCT07679919 opens enrollment
NCT07679919 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 1 intervention - of which LMY-922 is the first listed.
NCT07679919 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07679919 about?
NCT07679919 is a clinical study titled "BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies". Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory hematologic malignancies, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to...
What is the current status of trial NCT07679919?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2026-09. Estimated completion is 2029-04.
What interventions are being tested in trial NCT07679919?
The interventions under investigation include: LMY-922 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07679919?
This trial is sponsored by Luminary Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07679919's enrollment target sits among peer trials
27 1463rd of 2000 higher than 519 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia